- Home
- TC vs CDT Comparison
TC vs CDT Comparison
Compare TC & CDT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TC
- CDT
- Stock Information
- Founded
- TC 2010
- CDT 2019
- Country
- TC China
- CDT United States
- Employees
- TC N/A
- CDT N/A
- Industry
- TC Business Services
- CDT Biotechnology: Pharmaceutical Preparations
- Sector
- TC Consumer Discretionary
- CDT Health Care
- Exchange
- TC Nasdaq
- CDT Nasdaq
- Market Cap
- TC 2.4M
- CDT 2.2M
- IPO Year
- TC 2018
- CDT N/A
- Fundamental
- Price
- TC $0.85
- CDT $2.30
- Analyst Decision
- TC
- CDT
- Analyst Count
- TC 0
- CDT 0
- Target Price
- TC N/A
- CDT N/A
- AVG Volume (30 Days)
- TC 231.9K
- CDT 576.0K
- Earning Date
- TC 07-01-2025
- CDT 08-11-2025
- Dividend Yield
- TC N/A
- CDT N/A
- EPS Growth
- TC N/A
- CDT N/A
- EPS
- TC N/A
- CDT N/A
- Revenue
- TC $6,737,269.00
- CDT N/A
- Revenue This Year
- TC N/A
- CDT N/A
- Revenue Next Year
- TC N/A
- CDT N/A
- P/E Ratio
- TC N/A
- CDT N/A
- Revenue Growth
- TC N/A
- CDT N/A
- 52 Week Low
- TC $0.46
- CDT $2.23
- 52 Week High
- TC $4.30
- CDT $2,707.50
- Technical
- Relative Strength Index (RSI)
- TC 58.22
- CDT 25.60
- Support Level
- TC $0.77
- CDT $2.23
- Resistance Level
- TC $0.95
- CDT $2.59
- Average True Range (ATR)
- TC 0.08
- CDT 0.29
- MACD
- TC -0.01
- CDT 0.19
- Stochastic Oscillator
- TC 50.00
- CDT 3.48
About TC TuanChe Limited
Token Cat Ltd is an omnichannel automotive marketplace in China. The company operates in one segment, providing auto shows, special promotion event services, virtual dealerships, online marketing services, and more. It organizes auto shows to facilitate transactions between consumers and auto dealers, which include auto dealers, automakers, and automotive service providers. It offers services through its online platform and offline events.
About CDT Conduit Pharmaceuticals Inc.
Conduit Pharmaceuticals Inc is a clinical-stage specialty biopharmaceutical company that was formed to facilitate the development and commercialization of clinical assets that have not been or are not being prioritized by biopharmaceutical companies to develop pharmaceutical products that meet the unmet medical needs of patients. The Company's current development pipeline includes a glucokinase activator, which is Phase II ready for autoimmune diseases including uveitis, Hashimoto's Thyroiditis, preterm labor, and renal transplant rejection. The Company's development pipeline also includes a potent, irreversible inhibitor of human Myeloperoxidase (MPO) that has the potential to treat idiopathic male infertility.